Global Leading Market Research Publisher QYResearch announces the release of its latest report “Meningitis B Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Meningitis B Vaccine market, including market size, share, demand, industry development status, and forecasts for the next few years. For public health officials, pediatric infectious disease specialists, and vaccine industry investors, a persistent immunization gap has defined meningococcal disease prevention for decades: serogroup B (MenB). Unlike serogroups A, C, W, and Y (preventable by conjugate vaccines since the early 2000s), MenB's polysaccharide capsule—chemically similar to human neural cell adhesion molecules—is poorly immunogenic, rendering traditional polysaccharide conjugate vaccine approaches ineffective. The medical breakthrough arrived in the form of recombinant protein vaccines. Meningitis B Vaccine is a vaccine specifically designed to protect against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, a leading cause of bacterial meningitis and septicemia in infants, adolescents, and young adults worldwide. Two recombinant protein MenB vaccines have received regulatory approval: BEXSERO (GlaxoSmithKline, formerly Novartis), containing four recombinant proteins (fHbp, NadA, NHBA, PorA) and outer membrane vesicles, and TRUMENBA (Pfizer), containing two recombinant factor H binding protein (fHbp) subfamily variants. Both vaccines are non-interchangeable; vaccination series must be completed with the same product. As national immunization programs expand inclusion of MenB vaccines (UK, Australia, Italy, US CDC recommendations, and others) and outbreak responses require rapid deployment, the meningitis B vaccine market has evolved from niche specialty product to essential public health intervention. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/2641509/meningitis-b-vaccine Product Segmentation and Competitive Landscape The Meningitis B Vaccine market is segmented as below, featuring a competitive landscape dominated by two major vaccine manufacturers with recombinant protein technology: GlaxoSmithKline, Novartis (vaccine portfolio transferred to GSK), BEXSERO, TRUMENBA, Pfizer, Sanofi Pasteur Inc (manufactures MenACWY conjugate vaccines; no approved MenB vaccine), Wyeth Pharmaceuticals, Inc. (Pfizer subsidiary). Segment by Vaccine Type MenACWY (Conjugate) Vaccine: Protects against serogroups A, C, W, Y. Polysaccharide-protein conjugate technology. Not protective against serogroup B. Included in many adolescent immunization schedules. Mentioned in segmentation as comparator/co-administered product. MenB (Recombinant Protein) Vaccine: Protects specifically against serogroup B. Recombinant protein technology (BEXSERO and TRUMENBA). Non-interchangeable between products. Requires 2-3 dose series depending on age and product. The core focus of this report. Segment by Administration Setting Hospital: Inpatient vaccination for high-risk patients (asplenia, complement deficiency, laboratory workers), post-exposure prophylaxis, and outbreak response. Typically individual patient administration. Clinic: Routine childhood and adolescent immunization (pediatric clinics, school-based programs, travel health clinics). Volume segment for national immunization programs and routine catch-up vaccination. Market Dynamics and Strategic Considerations Public Health Drivers for Meningitis B Vaccine Adoption The clinical burden of MenB disease is substantial: approximately 30-50% of meningococcal disease cases in regions without universal MenB immunization are caused by serogroup B, with case fatality rates of 5-10% even with appropriate antibiotic treatment. Survivors may experience permanent sequelae including hearing loss, neurological disability, limb amputation, and skin scarring. The highest incidence occurs in infants under 1 year and adolescents/young adults 15-24 years (due to social behaviors including crowded living, smoking, bar attendance, and intimate kissing). National Immunization Program (NIP) Inclusion as Primary Growth Driver Unlike therapeutic vaccines where patient/physician choice drives adoption, meningitis B vaccine uptake is primarily determined by national and regional immunization policy. Key NIP decisions: United Kingdom: First country to introduce routine infant MenB vaccination (BEXSERO, 2015). Four-dose schedule (2, 4, 12 months) with booster at 13-14 years. Result: MenB cases in vaccine-eligible cohorts reduced by 75-80% within 3 years. Australia: National NIP inclusion (BEXSERO, 2018 for indigenous infants; 2024 expansion to all infants). Multiple-dose infant schedule. Italy: Regional variation; some regions (Tuscany, Veneto) include MenB in infant schedules; others do not. United States: CDC's Advisory Committee on Immunization Practices (ACIP) recommends MenB vaccination for adolescents and young adults at increased risk (persistent complement deficiency, asplenia, laboratory workers) and for healthy adolescents based on shared clinical decision-making (category B recommendation, not routine universal). Result: US MenB vaccination coverage remains low (approximately 30% for first dose, 15-20% for series completion) compared to MenACWY (85-90% coverage). For manufacturers, expansion of MenB vaccine into additional national immunization programs (potential candidates: France, Germany, Spain, Canada, Brazil, Japan) represents the highest-value growth opportunity. Each NIP inclusion adds 500,000-4 million annual doses at government-negotiated pricing (typically USD 40-90 per dose for public procurement versus USD 120-200 for private market). Product Differentiation: BEXSERO vs. TRUMENBA Although both vaccines are recombinant protein, important differences exist: Feature BEXSERO (GSK) TRUMENBA (Pfizer) Antigens 4 proteins + OMV 2 fHbp variants Age indication (US) 10-25 years 10-25 years Age indication (EU) 2 months+ 10-25 years (younger ages in some countries) Infant schedule 3 doses + booster Not indicated under 10 years in EU Dosing (adolescents) 2 doses 2 doses Booster recommendation Yes (after 1 year) Yes (after 1 year) Coadministration data Limited with MenACWY Extensive with MenACWY BEXSERO has advantage in infant indication (critical for public health impact). TRUMENBA has advantage in adolescent co-administration data with MenACWY vaccines (simplifying school-based programs). In markets where both are available (US, many European countries), product selection depends on age group targeted and regional immunization schedule structure. Emerging Candidates and Pipeline The MenB vaccine pipeline includes combination products (MenB+MenACWY pentavalent vaccines) to reduce number of injections. GSK and Pfizer both have combination candidates in early/late-stage development. A single pentavalent meningococcal vaccine (serogroups A, B, C, W, Y) would simplify immunization schedules and increase uptake. Regulatory approval (expected mid-2028 to 2030) would consolidate the MenB and MenACWY markets into a single product, potentially reducing MenB segment revenue through lower per-dose pricing but increasing overall meningococcal vaccine market volume through improved compliance. Exclusive Analyst Observation: The Post-Pandemic Catch-Up Opportunity The COVID-19 pandemic disrupted routine childhood immunization globally, leaving millions of children behind schedule. UNICEF and WHO data indicate that 25+ million children missed routine vaccinations in 2020-2022, with meningococcal vaccine coverage declining in many low- and middle-income countries. For MenB vaccine (recently introduced in many markets or not yet introduced), the catch-up vaccination campaigns represent a one-time demand surge as health systems work to restore coverage rates. In the UK, NHS England launched a MenB catch-up program in 2024 for infants who missed doses during pandemic lockdowns, adding 150,000-200,000 additional doses over baseline. Similar catch-up opportunities exist in Australia, Italy, Spain (regional), and other markets where MenB was NIP-included but coverage dipped. For manufacturers, engaging with public health authorities on catch-up campaign planning is a near-term (2025-2027) tactical opportunity distinct from routine NIP inclusion. Strategic Recommendations For public health officials and immunization program managers: evaluate MenB vaccine inclusion in national schedules based on disease burden (local MenB incidence relative to other serogroups), cost-effectiveness modeling, and infant/adolescent program delivery infrastructure. For countries with established MenACWY programs, adding pentavalent combination (once approved) may be easier than separate MenB and MenACWY administration. For product managers and marketing leaders at vaccine manufacturers: differentiate BEXSERO on infant indication and broad antigen coverage; differentiate TRUMENBA on adolescent co-administration data. For both, support health economic modeling for NIP decision-makers. Develop pentavalent combination vaccines to capture future market consolidation. For investors: the MenB vaccine market is a duopoly (GSK, Pfizer) with high barriers to entry (recombinant protein technology, clinical trial requirements, NIP relationships). Monitor NIP expansion decisions (France, Germany, Canada, Brazil, Japan) as demand catalysts. Watch pentavalent development timelines as potential market reconfiguration event. The Meningitis B Vaccine market represents a mature duopoly with steady growth driven by NIP inclusion expansion and catch-up campaigns. While not a high-growth market compared to oncology or rare disease biologics, its predictable demand, government procurement stability, and essential public health rationale support continued investment thesis for incumbent manufacturers. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp